Navigation Links
Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
Date:10/23/2007

--FDA Has Agreed That Positive Survival Data from IMPACT Study Would

Support Licensure of PROVENGE-

--Interim Survival Results Expected in Second Half of 2008--

SEATTLE, Oct. 23 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that the Company has completed enrollment of over 500 patients in the Phase 3 IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment, also known as D9902B) clinical trial of PROVENGE (sipuleucel-T), the Company's investigational active cellular immunotherapy for the treatment of advanced prostate cancer. The IMPACT study is a double-blind, randomized, placebo-controlled Phase 3 trial designed to measure overall survival in men with metastatic hormone-refractory prostate cancer receiving PROVENGE versus placebo.

Earlier this year, following a positive recommendation from an outside panel of experts, Dendreon received a complete response letter from the U.S. Food and Drug Administration (FDA) that asked for additional evidence that would support the efficacy of PROVENGE. Subsequently, Dendreon received confirmation that the FDA will accept either a positive interim or positive final analysis of overall survival from the IMPACT study to amend the Biologics License Application (BLA) and support the efficacy claim for PROVENGE.

"The completion of enrollment of over 500 patients into the IMPACT study is a major achievement for the organization, as the data from this trial may provide the FDA with the additional clinical data they need for the approval of PROVENGE," said Mitchell H. Gold, M.D., president and chief executive officer of Dendreon. "Men with late stage prostate cancer currently have few appealing treatm
'/>"/>

SOURCE Dendreon Corporation
Copyright©2007 PR Newswire.
All rights reserved

7

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Presentation of Data at American Urological Association Annual Meeting
2. Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
3. Celsion Completes Enrollment in Phase I Liver Cancer Study
4. LANI completes Phase I in Japan and to commence Phase I in UK
5. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
6. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
7. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
8. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
9. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
10. Two Phase III clinical trials on corifollitropin alfa (Org 36286) reach randomization target
11. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2013)... and WESTMINSTER, Colo. , June 20, 2013 ... US-based Surefire Medical today announced a sales and ... and specialty catheters for the interventional radiology and oncology markets. ... Surefire Medical range of products in the company,s rapidly growing ... Australia . Sirtex reported a 30 per ...
(Date:6/19/2013)... June 19, 2013 Pharmacyclics, Inc. (the "Company") ... The New England Journal of Medicine ( NEJM ... the investigational oral Bruton,s tyrosine kinase (BTK) inhibitor ibrutinib ... These data suggested ibrutinib may be effective and generally ... Results of a separate study examining the safety and ...
(Date:6/19/2013)... YORK , June 19, 2013 /PRNewswire-iReach/ -- ... pioneer of modern hair transplant procedures and founder ... was included in the ,Best Doctors, issue of ... (Photo:  http://photos.prnewswire.com/prnh/20130619/CG34629 ) ... Best Doctors issue, and his reputation as world-renowned ...
Breaking Medicine Technology:Sirtex To Distribute Surefire Medical's Innovative Infusion System in Australia and Asia Pacific Markets 2Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 2Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 3Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 4Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 5Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 6Dr. Robert Bernstein in NY Magazine's 'Best Doctors' Issue for 14th Consecutive Year 2Dr. Robert Bernstein in NY Magazine's 'Best Doctors' Issue for 14th Consecutive Year 3
(Date:6/20/2013)... 20, 2013 Anant Goel, CEO at ... to empower children and adults with skills of the 21st ... that form the foundation for success in the new millennium. ... having access to technology does not automatically make us the ... for work, businesses, and life." , The ...
(Date:6/20/2013)... 20, 2013 As a key researcher ... Navneet Tyagi has remained closely linked to neurodegenerative ... of scientific research that Tyagi has participated in, he ... onset of these severe and mysterious neurological conditions. It ... researchers will be able to understand about the nature ...
(Date:6/20/2013)... Washington, DC (PRWEB) June 20, 2013 ... exchanges, the executive director of the Maryland Health Benefit ... Hub — “something that many in the industry consider,” ... post on AISHealth.com, “as mythical as unicorns and ... actually connected to the Federal Data Services Hub live,” ...
(Date:6/20/2013)... Mobile, a leading manufacturer and distributor of wholesale-direct-to-consumer ... of 16GB version of the Mini Studio Android tablet. ... tablet that is a direct competitor to the iPad ... it will be launched at promotional price at $121 ... Mini STUDIO is part of the Handgiftbox.com “STUDIO Series,” ...
(Date:6/20/2013)... 2013 Emotional abuse expert and author, ... and confronting tactics used by emotional abusers. In ... and not being spoken to for days, being blamed ... experienced these behaviors and more in her marriage to ... marriage for 13 years because she did not realize ...
Breaking Medicine News(10 mins):Health News:RKNet Studio Launched Online Website for Fun Games, Brain Training and Cognitive Skills Development 2Health News:RKNet Studio Launched Online Website for Fun Games, Brain Training and Cognitive Skills Development 3Health News:Navneet Tyagi Supports Continued Efforts for Alzheimer Detection Procedures 2Health News:Navneet Tyagi Supports Continued Efforts for Alzheimer Detection Procedures 3Health News:Federal Data Services Hub Does Exist, AISHealth.com Blog Post Reports 2Health News:Android Tablet PC Mini Studio with Android 4.1 with 16GB is Here at $121 Only at Handgiftbox.com 2Health News:Lisa Kroulik Empowers Women to Recognize Emotional Abuse in Intimate Relationships 2
... future of nanotechnology without talking about or with Mike ... National Nanotechnology Initiative (NNI)Americas $8 billion federal investment in ... and industry. , Nanotechnology refers to the emerging ... usually at the 1-100 nanometers scale. The head of ...
... the years, lead is not intentionally added to cosmetics.,Lead ... in the,environment. Consumers are exposed daily to lead when ... amount of lead a woman would be exposed to,when ... she would get from,eating, breathing, and drinking water that ...
... Organizations to Leverage Network Connections to Facilitate International ... ... Internet2 today announced a new,Memorandum of Understanding (MOU) with Rede ... networking organization of,Brazil, to facilitate international telehealth and telemedicine,collaborations. The ...
... Transfer to Healthcare Marketplace -, ATLANTA, Oct. ... community management (BCM) solutions, today announced it,is sponsoring ... Electronic Data Interchange (WEDI) Conference on Health Savings,Accounts ... BizManager,suite and Secure Link solution. The conference is ...
... through 20, WASHINGTON, Oct. 11 U.S. ... start of the second annual Drug-Free,Work Week, which ... October 20. A,collaborative effort of the department and ... of being drug-free to,keeping workplaces safe., "Drug-free ...
... of U.S. adults feel comfortable discussing it , , THURSDAY, Oct. ... politics and religion, many Americans are reluctant to discuss managing ... new survey of more than 1,000 adults. , The survey, ... they knew someone with a chronic illness, but only 34 ...
Cached Medicine News:Health News:The nanotech future: a conversation with Mihail Roco 2Health News:Internet2 and Rede Nacional de Ensino e Pesquisa Form Health Sciences Partnership 2Health News:Internet2 and Rede Nacional de Ensino e Pesquisa Form Health Sciences Partnership 3Health News:Inovis Sponsors ASC X12 Conference, Exhibits BizManager and Secure Link 2Health News:U.S. Secretary of Labor launches Drug-Free Work Week 2Health News:Chronic Illness Often a Taboo Subject: Survey 2Health News:Chronic Illness Often a Taboo Subject: Survey 3
... is a non-invasive massage machine for ... the circulatory system. Extraordinary results are ... action, which combines vertical and parallel ... percussion, gyratory massage, deep tissue mobilization, ...
The Ritter 204 Manual Exam Table. Featuring the latest in design, comfort and functionality in a manual exam table, it truly offers efficient patient care....
... 622 and 623 High-Low Examination Tables deliver the ... you. Many different types of patients can ... how to get on the exam table. Being ... ,can increase a patients comfort during the exam, ...
... MegaPeel microdermabrasion systems offer many features that ... save you time and money. Because our ... easy to use and maintain, you spend ... your microdermabrasion equipment. MegaPeel microdermabrasion systems are ...
Medicine Products: